FibroGen
San Francisco
About FibroGen
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $358.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2023)
- Ticker: nasdaq:FGEN
- Website: fibrogen.com
- Phone: 415-978-1200
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/fibrogen-8225 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.